Form 4: Vertex Pharmaceuticals Executive Sells Shares Under Pre-Arranged Trading Plan
SEC Form 4 Filing
EVP Edward Morrow Atkinson III sold 883 shares of Vertex Pharmaceuticals common stock at $425.70 per share on February 26, 2024, according to a Form 4 filing with the SEC.
Summary
- On February 23, 2024, Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, had 1,654 shares withheld to cover taxes at a price of $431.79.
- On February 26, 2024, Atkinson sold 883 shares of Vertex Pharmaceuticals common stock at $425.70 per share.
- Following these transactions, Atkinson directly owns 15,972 shares of Vertex Pharmaceuticals.
- The sale was executed under a pre-arranged trading plan (Rule 10b5-1) established on August 22, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. They are often part of a pre-arranged trading plan, like the Rule 10b5-1 plan mentioned in the filing, which allows insiders to sell shares at predetermined times and prices to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/22/2023 | Date of entry into Rule 10b5-1 trading plan |
| 02/23/2024 | Withholding of 1,654 shares for taxes |
| 02/26/2024 | Sale of 883 shares at $425.70 per share |
| 02/27/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.